What is LTRN (LTRN) stock price today?

LTRN (LTRN) is currently trading at $2.63, down 0.75% today.

What is LTRN P/E ratio?

LTRN's P/E ratio is -2.02. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is LTRN return on equity (ROE)?

LTRN's return on equity (ROE) is -0.26%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is LTRN's market cap?

LTRN has a market capitalization of $33.56M.

NASDAQ · Biotechnology

LTRN (LTRN) Stock

$2.63 -0.75% NASDAQ: LTRN Healthcare

Valuation

Metric	Value
Price	$2.63
Market Cap	$33.56M
P/E Ratio	-2.02
P/B Ratio	0.01
P/S Ratio	0.00
EPS (TTM)	$-1.57
52-Week High	$5.74
52-Week Low	$1.11
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-0.26%
ROA	-0.15%
ROCE	-0.28%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.02
Current Ratio	2.40

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-13.0M	$-14.0M	$-18.0M	$-22.0M	$-18.0M
Net Profit	$-12.0M	$-14.0M	$-16.0M	$-21.0M	$-17.0M
EPS	$-1.13	$-1.31	$-1.47	$-1930.92	$-1.57
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$74.0M	$59.0M	$44.0M	$26.0M	$11.0B
Total Liabilities	$2.0M	$3.0M	$3.0M	$4.0M	$4.5B
Cash	$52.0M	$37.0M	$22.0M	$8.0M	$4.4B
Borrowings	$0	$0	$0	$0	$79.0M

Latest News

Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent "Computational Biologist" That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer Business Wire · Jul 8, 2026 Lantern Pharma Says Longer LP-300 Treatment Helped Lung Cancer Patients in Phase 2 Study MT Newswires · Jun 2, 2026 Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer Business Wire · Jun 2, 2026 Lantern Pharma (LTRN) Q1 2025 Earnings Transcript Motley Fool · May 21, 2026 Promising Penny Stocks To Consider In May 2026 Simply Wall St. · May 15, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-11.0M	$-13.0M	$-14.0M	$-18.0M	$-16.0M
Investing Cash Flow	$-20.0M	$0	$-1.0M	$3.0M	$11.0M
Financing Cash Flow	$-5.0M	$0	$0	$0	$0
Net Cash Flow	$33.0M	$-15.0M	$-16.0M	$-14.0M	$-3.0M
Free Cash Flow	$-11.0M	$-13.0M	$-14.0M	$-18.0M	$-16.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-37.27%
Quick Ratio	1.87
Interest Coverage	—
Return 1Y	-17.85%
Return 3Y	-37.60%
Return 5Y	-76.24%

Ownership

Insiders Held17.15%

Institutions Held14.16%

Institutions Float Held17.09%

Institutional Holder	Shares	Report Date
Bios Capital Management, LP	864,435	2026-03-31
Vanguard Capital Management LLC	332,079	2026-03-31
CM Management, LLC	250,000	2026-03-31
Renaissance Technologies, LLC	116,000	2026-03-31
Geode Capital Management, LLC	111,646	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ANVS	$1.70	+0.59%	-1.54	$33.45M	0.00%
ATNM	$0.80	+1.32%	-1.07	$25.02M	0.00%
BCABBioAtla, Inc.	$3.40	+0.89%	-0.08	$4.29M	0.00%
CALCCalciMedica, Inc.	$0.73	-3.82%	-0.57	$11.55M	0.00%
ELUT	$0.86	-5.33%	-1.24	$37.88M	0.00%

About LTRN

LTRN is led by CEO Panna Sharma, employs 24 people, headquartered in US, publicly traded since 2020.

LTRN stock trades at $2.63 with a market capitalization of $33.56M. The stock is valued at a price-to-earnings (P/E) ratio of -2.02, price-to-book of 0.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.11 and $5.74, and currently trades 54.2% below its 52-week high.

On profitability, LTRN generates a return on equity (ROE) of -0.26%, return on capital employed of -0.28%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides